KRO reports Q2 results today against a backdrop where positioning is remarkably calm — but the analyst community has been moving firmly in one direction.
The lending market signals no meaningful bearish pressure. Availability is running at roughly 677%, meaning there are nearly seven shares available to borrow for every one already lent out — far looser than even the 52-week tightest point of 248%. Cost to borrow is just 0.51%, down around 15% over the past month. Short interest itself has drifted lower this week, slipping roughly 7% to around 1.5 million shares. The options market corroborates the relaxed tone: the put/call ratio of 0.38 is slightly below its 20-day average and sits nowhere near the defensive extreme of 0.98 reached earlier this year. The stock has recovered about 4% over the past month to close at $6.21, though it slipped fractionally on Wednesday.
The real tension into this print is between a deeply discounted stock and a Street that has been consistently cutting its view. Goldman Sachs, the most active voice on the name, trimmed its target to $5.00 in December from $6.00 — maintaining a Sell rating it has held throughout — while Barclays cut to $7.00 from $10.00 in May 2025, also holding Underweight. The consensus mean target of $6.50 sits only marginally above the current price, implying the Street sees limited upside even after a 36% year-to-date run. The bull case rests on valuation: KRO trades well below book (price-to-book near 0.75) with EV/EBITDA around 4.8x, and the ORTEX value factor score is among the highest in its chemical peer group. Bears point to structural weakness — a negative five-year EBIT trend, an Altman Z-score in distress territory at 1.39, and declining sales — suggesting the cheap multiple reflects genuine fundamental risk rather than an overlooked opportunity.
One structural detail stands out: Contran Corporation controls 81% of the shares, leaving only a thin public float. That ownership concentration constrains any short-squeeze dynamic and means institutional activity among the remaining holders carries outsized weight. Director Kevin Kramer bought just under $100,000 worth of stock in May near $6.73, the most recent insider activity on record. Closest peer TROX gained 4.2% on Wednesday while KRO barely moved, and CC rose nearly 5% on the week — leaving KRO as a modest laggard despite its year-to-date outperformance.
The Q2 report is therefore less about sentiment extremes — there are none — and more about whether titanium dioxide pricing and volumes can justify a valuation that looks cheap on paper but has consistently failed to attract meaningful analyst conviction.
See the live data behind this article on ORTEX.
Open KRO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
